Clinical Trials Browser

1-dodecylpyridoxal × Clear all

NCT07564141 2026-06-03

RAINFOL™-07

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT06843447 2026-05-26

MK-5909-003

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05271318 2026-05-05

PROTA

Phase 1/2 Active not recruiting

Adenoviridae Infections

NCT05551507 2026-05-04

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Phase 1/2 Recruiting

Platinum-resistant Ovarian Cancer

NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Phase 2/3 Active not recruiting

Ovarian Neoplasms

NCT06425302 2026-01-08

GOLSEEK-2

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Follicular

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06014528 2025-04-30

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Phase 2 Recruiting

Ovarian Cancer Recurrent

NCT06687070 2025-02-26

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Phase 1 Recruiting

GynecologicOther solid neoplasm

Platinum-resistant Recurrent Ovarian Cancer

NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Phase 1 Completed

19 enrolled 21 charts

Ovarian Neoplasms, Peritoneal Neoplasms

NCT05261490 2024-11-19

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Phase 1/2 Terminated

10 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03907969 2024-02-06

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

Phase 1/2 Completed

30 enrolled 17 charts

Advanced Malignancies

NCT04244552 2023-12-29

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Phase 1 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04877275 2023-12-06

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Phase 2 Unknown

Multiple Myeloma

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Phase 2 Terminated

Multiple Myeloma

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence

NCT04172259 2023-10-16

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Phase 2 Active not recruiting

Breast Neoplasms

NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

95 enrolled 61 charts

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

NCT05201001 2023-09-11

APX005M

Phase 2 Withdrawn

Ovarian Neoplasms

NCT05976932 2023-08-04

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

Ovarian Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

Phase 3 Completed

566 enrolled 40 charts

Ovarian Neoplasms

NCT05868889 2023-05-24

Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD

Ovarian Neoplasms

NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03161132 2023-01-27

ROLANDO

Phase 2 Completed

Advanced Ovarian Cancer

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

53 enrolled 22 charts

Ovarian Neoplasms

NCT05346107 2022-04-26

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00785798 2022-04-04

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Phase 1/2 Terminated

17 enrolled 4 charts

Lymphoma

NCT04348032 2022-03-31

APPROVE

Phase 2 Unknown

Platinum-resistant Recurrent Ovarian Cancer

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Phase 3 Terminated

Ovarian Neoplasms

NCT04887961 2021-08-09

MITO36

Phase 2 Unknown

Ovarian Neoplasms

NCT04983550 2021-07-30

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01837251 2021-07-13

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT03268772 2020-04-22

PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS

Phase 2 Unknown

Sarcoma

NCT02644278 2019-09-09

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Phase 1 Completed

15 enrolled 13 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03952572 2019-05-16

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Phase 3 Unknown

Lymphoma, T-Cell, Peripheral

NCT03949634 2019-05-14

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Phase 3 Unknown

Breast Neoplasms

NCT03123770 2019-04-10

ESNDBCP

Phase 4 Unknown

Breast Neoplasms

NCT03562533 2019-02-28

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Neoplasms

NCT03446495 2018-02-26

Renaissance

Ovarian Neoplasms

NCT03419494 2018-02-05

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01281254 2017-12-02

TRINOVA-2

Phase 3 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01991210 2017-08-21

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

Phase 2 Terminated

Ovarian Neoplasms

NCT00550771 2017-06-07

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

Phase 2 Completed

181 enrolled 9 charts

Breast Neoplasms

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Phase 1 Terminated

2 enrolled 5 charts

Ovarian Neoplasms

NCT01004380 2014-07-17

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00750815 2014-01-20

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Phase 1/2 Completed

58 enrolled 11 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT01051362 2010-01-18

Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung